Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Large Growth in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 536,900 shares, a growth of 97.7% from the December 15th total of 271,600 shares. Currently, 0.7% of the company’s stock are sold short. Based on an average daily volume of 828,700 shares, the short-interest ratio is currently 0.6 days.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. boosted its stake in Cocrystal Pharma by 108.7% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 24,243 shares of the company’s stock valued at $25,000 after purchasing an additional 12,625 shares during the period. LPL Financial LLC boosted its stake in Cocrystal Pharma by 10.4% in the 2nd quarter. LPL Financial LLC now owns 153,500 shares of the company’s stock valued at $192,000 after purchasing an additional 14,500 shares during the period. Barclays PLC boosted its stake in Cocrystal Pharma by 248.5% in the 3rd quarter. Barclays PLC now owns 26,665 shares of the company’s stock valued at $28,000 after purchasing an additional 19,014 shares during the period. Goldman Sachs Group Inc. boosted its stake in Cocrystal Pharma by 14.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 157,952 shares of the company’s stock valued at $166,000 after purchasing an additional 19,784 shares during the period. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Cocrystal Pharma during the 2nd quarter valued at $50,000. Institutional investors and hedge funds own 15.70% of the company’s stock.

Shares of NASDAQ COCP opened at $0.60 on Friday. Cocrystal Pharma has a 12 month low of $0.56 and a 12 month high of $3.46. The stock has a 50 day moving average of $0.76 and a 200-day moving average of $0.96.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Monday, November 15th. The company reported ($0.04) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). On average, research analysts expect that Cocrystal Pharma will post -0.15 EPS for the current year.

Separately, Zacks Investment Research raised Cocrystal Pharma from a “sell” rating to a “hold” rating in a research report on Monday, January 10th.

About Cocrystal Pharma

Cocrystal Pharma, Inc is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Featured Story: Bond

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.